Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma

Abstract Glioblastoma (GBM) is the leading cause of high fatality cancer arising within the adult brain. Electrotherapeutic approaches offer new promise for GBM treatment by exploiting innate vulnerabilities of cancer cells to low intensity electric fields. This report describes the preclinical outc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea R. Di Sebastiano, Andrew Deweyert, Simon Benoit, Erin Iredale, Hu Xu, Cleusa De Oliveira, Eugene Wong, Susanne Schmid, Matthew O. Hebb
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1f05a2ae04fe4064a4a868d526562962
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1f05a2ae04fe4064a4a868d526562962
record_format	dspace
spelling	oai:doaj.org-article:1f05a2ae04fe4064a4a868d5265629622021-12-02T11:40:16ZPreclinical outcomes of Intratumoral Modulation Therapy for glioblastoma10.1038/s41598-018-25639-72045-2322https://doaj.org/article/1f05a2ae04fe4064a4a868d5265629622018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-25639-7https://doaj.org/toc/2045-2322Abstract Glioblastoma (GBM) is the leading cause of high fatality cancer arising within the adult brain. Electrotherapeutic approaches offer new promise for GBM treatment by exploiting innate vulnerabilities of cancer cells to low intensity electric fields. This report describes the preclinical outcomes of a novel electrotherapeutic strategy called Intratumoral Modulation Therapy (IMT) that uses an implanted stimulation system to deliver sustained, titratable, low intensity electric fields directly across GBM-affected brain regions. This pilot technology was applied to in vitro and animal models demonstrating significant and marked reduction in tumor cell viability and a cumulative impact of concurrent IMT and chemotherapy in GBM. No off target neurological effects were observed in treated subjects. Computational modeling predicted IMT field optimization as a means to further bolster treatment efficacy. This sentinel study provides new support for defining the potential of IMT strategies as part of a more effective multimodality treatment platform for GBM.Andrea R. Di SebastianoAndrew DeweyertSimon BenoitErin IredaleHu XuCleusa De OliveiraEugene WongSusanne SchmidMatthew O. HebbNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andrea R. Di Sebastiano Andrew Deweyert Simon Benoit Erin Iredale Hu Xu Cleusa De Oliveira Eugene Wong Susanne Schmid Matthew O. Hebb Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
description	Abstract Glioblastoma (GBM) is the leading cause of high fatality cancer arising within the adult brain. Electrotherapeutic approaches offer new promise for GBM treatment by exploiting innate vulnerabilities of cancer cells to low intensity electric fields. This report describes the preclinical outcomes of a novel electrotherapeutic strategy called Intratumoral Modulation Therapy (IMT) that uses an implanted stimulation system to deliver sustained, titratable, low intensity electric fields directly across GBM-affected brain regions. This pilot technology was applied to in vitro and animal models demonstrating significant and marked reduction in tumor cell viability and a cumulative impact of concurrent IMT and chemotherapy in GBM. No off target neurological effects were observed in treated subjects. Computational modeling predicted IMT field optimization as a means to further bolster treatment efficacy. This sentinel study provides new support for defining the potential of IMT strategies as part of a more effective multimodality treatment platform for GBM.
format	article
author	Andrea R. Di Sebastiano Andrew Deweyert Simon Benoit Erin Iredale Hu Xu Cleusa De Oliveira Eugene Wong Susanne Schmid Matthew O. Hebb
author_facet	Andrea R. Di Sebastiano Andrew Deweyert Simon Benoit Erin Iredale Hu Xu Cleusa De Oliveira Eugene Wong Susanne Schmid Matthew O. Hebb
author_sort	Andrea R. Di Sebastiano
title	Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
title_short	Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
title_full	Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
title_fullStr	Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
title_full_unstemmed	Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma
title_sort	preclinical outcomes of intratumoral modulation therapy for glioblastoma
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/1f05a2ae04fe4064a4a868d526562962
work_keys_str_mv	AT andreardisebastiano preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT andrewdeweyert preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT simonbenoit preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT eriniredale preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT huxu preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT cleusadeoliveira preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT eugenewong preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT susanneschmid preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma AT matthewohebb preclinicaloutcomesofintratumoralmodulationtherapyforglioblastoma
_version_	1718395626963599360

Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma

Ejemplares similares